Protalex Inc (PRTX) financial statements (2021 and earlier)
Company profile
| Business Address |
131 COLUMBIA TURNPIKE FLORHAM PARK, NJ 07932 |
| State of Incorp. | DE |
| Fiscal Year End | May 31 |
| SIC | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 5/31/2018 | 5/31/2017 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 1 | 0 | 0 | 1 | 2 | 2 | ||
| Cash and cash equivalents | 1 | 0 | 0 | 1 | 2 | 2 | ||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total current assets: | 1 | 1 | 0 | 1 | 2 | 2 | ||
| Noncurrent Assets | ||||||||
| Intangible assets, net (including goodwill) | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Intangible assets, net (excluding goodwill) | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | 0 | ||
| TOTAL ASSETS: | 1 | 1 | 1 | 1 | 2 | 3 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 1 | 1 | 1 | 1 | 0 | 1 | ||
| Accounts payable | 0 | 0 | 1 | 0 | 0 | 1 | ||
| Accrued liabilities | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Debt | 4 | |||||||
| Total current liabilities: | 1 | 1 | 1 | 1 | 0 | 5 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 0 | |||||||
| Long-term debt, excluding current maturities | 0 | |||||||
| Liabilities, other than long-term debt | 2 | 20 | 16 | 13 | 9 | |||
| Due to related parties | 2 | 20 | 16 | 13 | 9 | |||
| Other undisclosed noncurrent liabilities | 0 | 1 | 1 | 0 | 0 | 6 | ||
| Total noncurrent liabilities: | 2 | 22 | 17 | 13 | 9 | 6 | ||
| Total liabilities: | 3 | 22 | 18 | 14 | 10 | 11 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (2) | (22) | (17) | (13) | (8) | (8) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 102 | 77 | 77 | 73 | 65 | 53 | ||
| Accumulated deficit | (104) | (99) | (95) | (85) | (74) | |||
| Other undisclosed stockholders' equity attributable to parent | (62) | |||||||
| Total stockholders' equity: | (2) | (22) | (17) | (13) | (8) | (8) | ||
| TOTAL LIABILITIES AND EQUITY: | 1 | 1 | 1 | 1 | 2 | 3 | ||
Income statement (P&L) ($ in millions)
| 5/31/2018 | 5/31/2017 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (4) | (3) | (8) | (11) | (11) | (5) | |
| Other undisclosed operating loss | (1) | (1) | (1) | (1) | (1) | (0) | |
| Operating loss: | (4) | (4) | (9) | (11) | (12) | (6) | |
| Nonoperating income (Investment Income, Nonoperating) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest and debt expense | (1) | (1) | (0) | (0) | (0) | (1) | |
| Loss from continuing operations before income taxes: | (5) | (5) | (9) | (12) | (12) | (6) | |
| Income tax expense | (5) | (5) | |||||
| Net loss: | (5) | (5) | (9) | (16) | (17) | (6) | |
| Other undisclosed net income attributable to parent | 5 | 5 | |||||
| Net loss available to common stockholders, diluted: | (5) | (5) | (9) | (12) | (12) | (6) | |
Comprehensive Income ($ in millions)
| 5/31/2018 | 5/31/2017 | 5/31/2016 | 5/31/2015 | 5/31/2014 | 5/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (5) | (5) | (9) | (16) | (17) | (6) | |
| Comprehensive loss, net of tax, attributable to parent: | (5) | (5) | (9) | (16) | (17) | (6) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.